|

Glofitamab Clinical Trials

26 actively recruiting trials across 16 locations

▼ -1 trial since May 2026

Also known as: Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody RO7082859, Anti-CD3 Bispecific Monoclonal Antibody RO7082859, CD20 TCB, Columvi, Columvi 10 mg +5 more

Pipeline

Phase 1: 4Phase 2: 14Phase 3: 1Phase 1/2: 4

Top Sponsors

  • Hoffmann-La Roche5
  • City of Hope Medical Center2
  • University of Washington1
  • University of California, San Francisco1
  • University Health Network, Toronto1

Indications

  • Cancer26
  • Mantle Cell Lymphoma5
  • Lymphoma3
  • DLBCL - Diffuse Large B Cell Lymphoma2
  • Diffuse Large B-cell Lymphoma(DLBCL)2

Other8 trials

A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure.
Phase 2
A Study of Efficacy and Safety of Glofitamab in Combination With Salvage Therapy in a Real-world Setting in Chinese Adult Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.
An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma
Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL)
Phase 2
Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma
Phase 2
Glofitamab in Chinese Patients With R/R DLBCL
MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)
Phase 2
Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma
Phase 2

Duarte, California3 trials

Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

City of Hope Medical Center

Phase 2
Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma

City of Hope Medical Center

Phase 1/2
Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy

City of Hope Comprehensive Cancer Center

Phase 2

Birmingham, Alabama1 trial

A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma

Children's Hospital of Alabama

Phase 1/2

Anchorage, Alaska1 trial

A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

Alaska Oncology & Hematology, LLC

Phase 2

Phoenix, Arizona1 trial

A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

Mayo Clinic Phoenix

Phase 1/2

Berkeley, California1 trial

A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

Alta Bates Summit Medical Center

Phase 3

Clovis, California1 trial

A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

University of California San Francisco - Fresno Center for Medical Education and Research

Phase 1

Davis, California1 trial

Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

University of California, Davis

Phase 2

La Jolla, California1 trial

A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

UC San Diego Moores Cancer Center

Phase 1

New Haven, Connecticut1 trial

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

Clinical Trial Site

Phase 1

Miami, Florida1 trial

A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma

University of Miami Sylvester Cancer Center

Phase 2

Atlanta, Georgia1 trial

Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

Winship Cancer Institute at Emory University

Phase 2

Omaha, Nebraska1 trial

CAR-T Followed by Bispecific Antibodies

University of Nebraska Medical Center

Phase 2

Basking Ridge, New Jersey1 trial

A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Phase 2

Portland, Oregon1 trial

Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial

OHSU Knight Cancer Institute

Phase 1/2

Houston, Texas1 trial

A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma

MD Anderson Cancer Center

Phase 2

Seattle, Washington1 trial

Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma

Fred Hutch/University of Washington Cancer Consortium

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.